Peptide therapeutics are short chains of amino acids linked in a specific order and are commonly used as drugs for various medical treatments. They are mainly used for cancer treatment, metabolic disorders, cardiovascular ailments, and other chronic conditions. Peptide therapeutics offer advantages like high selectivity, fewer side effects, and better affinity to receptors compared to traditional small molecule drugs. The rising cases of chronic diseases and need for more effective targeted therapies are fueling the demand for peptide therapeutics globally.
The Global peptide therapeutics market is estimated to be valued at US$ 51133.71 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period 2024 to 2030.
Key players operating in the peptide therapeutics market are IBM Corporation, SAP SE, Oracle Corporation, ABB Ltd., Infor, Inc., Ultimo Software Solutions BV, CARL International SA, eMaint Enterprises, LLC, Mainsaver, Inc., MEX Pty Ltd., Asset Works LLC, and CGI, Inc. These players are engaged in new product development and strategic collaborations to strengthen their market presence.
The key opportunities in the peptide therapeutics market include development of self-administrable delivery systems, rise in generic peptide drugs, and technological advancements in peptide manufacturing processes like solid-phase peptide synthesis.
Advancements in therapeutic peptides applications for neurodegenerative diseases, cardiovascular disorders, and metabolic conditions along with continuous developments in efficient solid-phase peptide synthesis technologies are projected to boost the peptide therapeutics market during the forecast period.
Market Drivers
The increasing prevalence of chronic diseases worldwide coupled with the rising geriatric population susceptible to various age-related ailments are major factors driving the Global Peptide Therapeutics Market Size. As per WHO estimates, chronic diseases accounted for 60% of global deaths in 2016. Moreover, peptides offer several advantages over small-molecule drugs such as low toxicity, high specificity, and low risk of immunogenicity, thus propelling their adoption. Additionally, significant R&D investments by governments and pharmaceutical companies and easier regulatory pathways for peptide drugs are expected to fuel market growth during the analysis period.
Challenges in Peptide Therapeutics Market
The peptide therapeutics market is facing various challenges currently which include high research and development costs associated with the development of novel peptide drugs. Peptide drug development requires extensive research and screening of various peptide sequences for desired therapeutic activity which significantly drives up costs. Maintaining stability of peptide drugs also remains a major challenge due to their susceptibility to degradation by proteases present in blood and tissues. Developing effective drug delivery methods for peptide drugs is another challenge mainly due to their large molecular size and poor membrane permeability.
SWOT Analysis
Strength: Peptides have high selectivity and specificity for their targets. They also have minimal side effects compared to small molecule drugs.
Weakness: High research and development costs involved. Poor membrane permeability of peptides also poses challenge for oral delivery.
Opportunity: Growing prevalence of chronic diseases is driving research on novel peptide therapeutics. Advances in prodrug strategies and drug delivery technologies also present opportunities.
Threats: Complex manufacturing processes increase production costs of peptide drugs. Stiff competition from conventional drugs remains a threat.
In terms of value, North America currently accounts for the largest share in the peptide therapeutics market due to advanced healthcare infrastructure and high adoption of specialty medicines. Europe is another major region driven by increasing research collaborations between pharmaceutical companies and research institutions. The Asia Pacific region is emerging as the fastest growing market for peptide therapeutics due to rising healthcare spending, growing burden of chronic diseases and expanding generic drug manufacturing capabilities in the region.
The United States represents the most concentrated geographical region currently for the peptide therapeutics market in terms of value. This is mainly attributed to the presence of advanced healthcare system, availability of funding for research and development activities. China is identified as the fastest growing geographical region for peptide therapeutics market over the forecast period owing to rapidly growing pharmaceutical industry, availability of low-cost manufacturing capabilities and increasing prevalence of lifestyle-related diseases in th region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it